Dr. Cathy Eng on Bevacizumab Plus FOLFOXIRI for Patients With mCRC

Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC). Eng says the combination came about through medical professional's use of bevacizumab in the frontline as a treatment for mCRC, leading one Italian research group to start the TRIBE trial.

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/

• #education
• #targeted_oncology
• #oncology
• #cancer
• #mcrc